Toll-like Receptor (TLR) Agonist

ODN D-SL01, a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. ODN D-SL01 has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3'.

Flagellin from S. typhimurium is a potent TLR5 agonist. Flagellin from S. typhimurium activates immune cells and inhibits the activity of melanoma cells. Flagellin from S. typhimurium activates the NF-κB pathway dependent on the TLR5/MyD88/TRAF6 signaling axis in cells. Flagellin from S. typhimurium induces a proinflammatory response in the primary chicken hepatocyte-nonparenchymal cell co-culture system by promoting IL-8 production, inhibiting IL-10 production, and increasing the IFN-γ/IL-10 ratio. Flagellin from S. typhimurium can be used for research on melanoma and inflammatory diseases.

ODN 2336 is a A-Class CpG ODN (oligodeoxynucleotides), is a potent TLR9 agonist. ODN 2336 induces the production of IFN-α. ODN 2336 up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 can be used as adjuvant of vaccines.

1Z105 is an orally active TLR4/MD2 agonist, immunostimulant and vaccine adjuvant. 1Z105 activates NF-κB via the MyD88/TRIF pathway in a CD14-independent manner, with EC₅₀ values of 0.63 µM and 0.77 µM for inducing IL-6 and IL-12 in mBMDCs, respectively. 1Z105 promotes dendritic cell maturation, antigen uptake and cross-presentation; when used alone, it induces Th2-IgG1, while combined with the TLR7 agonist 1V270, it synergistically induces balanced Th1/Th2 responses and provides low-reactogenic protection against homologous, heterologous and heterosubtypic influenza. 1Z105 prevents LPS (HY-D1056A1)- and galactosamine-induced liver injury as well as autoantibody-driven arthritis in mice. 1Z105 can be used in studies related to influenza virus infection, inflammation, and LPS/galactosamine-induced liver injury.

TLR7 agonist 6 (compound IIb-19) is an TLR7 agonist with an EC₅₀ value of 1.0 nM.

TLR4 agonist-1 (compound 17a) is a potent agonist of Toll-like Receptor 4 (TLR4), and induces the generation of MIP-1β in RAW 264.7 and MM6 cells.

Pam3CSK4-Biotin (Pam3Cys-Ser-(Lys)4-Biotin) TFA is biotinylated Pam3CSK4. Pam3CSK4-Biotin TFA is a Toll-like receptor 1/2 (TLR1/2) agonist.

MTvkPABC-P5d, a TLR7 agonist, is an immune stimulant. MTvkPABC-P5d can be used for synthesis of immune-stimulating antibody conjugates (ISACs).

TLR7/8 agonist 8 (compound 24m) is a potent toll-like receptor 7/8 (TLR7/8) dual agonist, with EC₅₀s of 27 and 12 nM for hTLR7 and hTLR8, respectively. TLR7/8 agonist 8 can improve the antitumor activity of PD-1/PD-L1 blockade.

SMU-Z1 is a TLR1/2 heterodimer agonist with an EC₅₀ of 4.88 nM. SMU-Z1 activates the NF-κB pathway, triggers pro-inflammatory cytokine production, and induces the generation of TNF-α, IL-1β, IL-6 and NO. SMU-Z1 promotes splenocyte proliferation and upregulates the expression of CD8⁺T cells, NK cells and dendritic cells. SMU-Z1 exhibits significant anti-tumor effects in mouse leukemia models. SMU-Z1 can be used for leukemia-related research.

Diprovocim-X (compound 35) is a potent TLR1/TLR2 (toll-like receptor 1/2) agonist, with EC₅₀ values of 0.14 and 0.75 nM for hTLR1/TLR2 and mTLR1/TLR2, respectively. Diprovocim-X is a potent adjuvant in vivo in mice, and serves to stimulate the adaptive immune response.

Cobitolimod is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod suppresses Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway.

Monophosphoryl Lipid A-12 (MPLA-12) is a Toll-like receptor 4 agonist. Monophosphoryl Lipid A-12 can be used for the research of immunization and vaccine.

a15:0-i15:0 PE is an atypical TLR2 agonist, and its immune signaling strictly depends on the TLR2-TLR1 heterodimer. a15:0-i15:0 PE induces dendritic cells to produce TNFα and IL-6, but does not induce the production of IL-10 or IL-12p70. At low doses, a15:0-i15:0 PE resets the activation threshold of immune cells to suppress or regulate immune responses against specific agonists.

Sotirimod (R850) is a TLR7 agonist and immunomodulator. Sotirimod inhibits Apoptosis. Sotirimod is applicable to research related to actinic keratosis, early cervical HPV infection, and precancerous lesions of colorectal cancer.

FAM labled Zoratolimodis a FAM labled Zoratolimod.

Cy3 labled Zoratolimod is a Cy3 labled Zoratolimod.

Polvitolimod is a TLR7 agonist for research of cancer and infectious disease.

Guretolimod (DSP-0509) is a Toll-like receptor 7 (TLR7) agonist.

TLR7/8 agonist 4 TFA (compound 41) is a potent TLR7/8 agonist. TLR7/8 agonist 4 TFA has anti-cancer activity.